The company, based at Umeå Biotech Incubator, is developing an innovative mucoadhesive ‘patch’ for mouth ulcers (aphthous stomatitis), one of the most common oral mucosal diseases. 

“We aim to be a leading global research and development company. This is a crucial component in our IPR portfolio and underscores our commitment to an ambitious IPR and market strategy. This approval is a significant step forward in our global growth strategy,” said Jean Lycke, Project Manager at Mucocort AB.

This product/technology had previously received approval under the European Patent System (EPC). Mucocort is now actively working to extend its patent protection to additional countries, further bolstering the global security of its product.